Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure.

[1]  G. Khursigara,et al.  Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria , 2010, American journal of hematology.

[2]  M. Gladwin,et al.  Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria , 2010, British journal of haematology.

[3]  N. Young,et al.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. , 2008, Blood.

[4]  N. Young,et al.  Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. , 2007, Blood.

[5]  N. Young,et al.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.

[6]  J. Rimola,et al.  The kidney in paroxysmal nocturnal haemoglobinuria: MRI findings. , 2004, The British journal of radiology.

[7]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[8]  L. Matis,et al.  Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. , 1996, Molecular immunology.

[9]  I. Anno,et al.  Paroxysmal Nocturnal Hemoglobinuria: MR Findings , 1993, Journal of computer assisted tomography.

[10]  D. Turner,et al.  MRI of the kidneys in paroxysmal nocturnal hemoglobinuria. , 1986, AJR. American journal of roentgenology.

[11]  S. Butler,et al.  The kidneys in paroxysmal nocturnal hemoglobinuria. , 1981, Blood.